

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

**Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking.**

Natalie S. Shenker,<sup>1</sup> Silvia Polidoro,<sup>2</sup> Karin van Veldhoven,<sup>2,3</sup> Carlotta Sacerdote,<sup>2</sup> Fulvio Ricceri,<sup>2</sup> Mark A. Birrell,<sup>4</sup> Maria G. Belvisi,<sup>4</sup> Robert Brown,<sup>1</sup> Paolo Vineis,<sup>2,3</sup> and James M. Flanagan<sup>1\*</sup>

1. Epigenetics Unit, Department of Surgery and Cancer, Imperial College London, W12 0NN, UK.

2. HuGeF Foundation, 52, Via Nizza, Torino, 10126, Italy.

3. MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG, UK.

4. Respiratory Pharmacology Group, National Heart and Lung Institute, South Kensington Campus, Exhibition Road, Imperial College London. London SW7 2AZ, UK.

The authors wish it to be known that the first two authors should be regarded as joint First Authors.

**\*Address for correspondence:**

Dr. James M. Flanagan

Epigenetics Unit, Division of Cancer, Department of Surgery and Cancer,  
Faculty of Medicine, Imperial College London

4<sup>th</sup> Floor IRDB, Hammersmith Campus, Du Cane Road, London W12 0NN

Tel: 020 75942127; fax: 020 75942129; email: [j.flanagan@imperial.ac.uk](mailto:j.flanagan@imperial.ac.uk)

Shenker et al.

## Abstract

A single CpG site within *F2RL3* was recently found to be hypomethylated in peripheral blood genomic DNA from smokers compared to former and non-smokers. We performed two epigenome-wide association studies (EWAS) nested in a prospective healthy cohort using the Illumina 450K Methylation Beadchip. The two populations consisted of matched pairs of healthy individuals (n=374), of which half went on to develop breast or colon cancer. The association was analysed between methylation and smoking status, as well as cancer risk. In addition to the same locus in *F2RL3*, we report several loci that are hypomethylated in smokers compared to former and non-smokers, including an intragenic region of the aryl hydrocarbon receptor repressor gene (*AHRR*; cg05575921,  $p=2.31 \times 10^{-15}$ ; effect size = 14%-17%), an intergenic CpG island on 2q37.1 (cg21566642,  $p=3.73 \times 10^{-13}$ ; effect size = 12%), and a further intergenic region at 6p21.33 (cg06126421,  $p=4.96 \times 10^{-11}$ , effect size = 7%-8%). Bisulphite pyrosequencing validated six loci in a further independent population of healthy individuals (n=180). Methylation levels in *AHRR* were also significantly decreased ( $p<0.001$ ) and expression increased ( $p=0.0047$ ) in the lung tissue of current smokers compared to non-smokers. This was further validated in a mouse model of smoke exposure. We observed an association with breast cancer risk for the 2q37.1 locus ( $p=0.003$ , adjusted for smoking status), but not for the other loci associated with smoking. These data show that smoking has a direct effect on the epigenome in lung tissue, which is also detectable in peripheral blood DNA and may contribute to cancer risk.

Shenker et al.

## Introduction

Epigenetic profiles, including methylation of the 5-carbon of cytosines, are helping to unravel the pathogenesis of numerous complex diseases, in particular for diseases that have an environmental component to their etiology. Since the first studies by Doll in the 1950s that linked smoking with lung cancer risk, smoking has been identified as a major risk factor for numerous cancers.

However, the molecular changes that occur as a consequence of the neoplastic process itself, in addition to changes caused by chemo- and radiotherapy, mean that any investigation into the epigenetic alterations induced by cancer risk factors must be performed prospectively in pre-diagnostic samples.

Improvements in array-based technology have enabled the molecular effects of altered environments, such as cigarette smoke inhalation, to be assessed in larger populations. The only study to show a significant link between smoking and the epigenome used the Illumina 27K platform and identified a single locus in the *F2RL3* gene out of 27,578 loci tested that was less methylated in current smokers (n = 65) compared to former (n = 56) and non-smokers (n = 56).(1) This gene is associated with platelet activation and coagulation, but cannot be clearly connected to the carcinogenic processes that are induced by an individual's exposure to tobacco smoke.

The introduction of the Illumina 450K methylation bead array has enabled the analysis of the DNA methylation pattern across the genome with additional coverage of promoters, 5'UTRs, first exons, gene bodies and 3'UTRs. This study aimed to assess the impact of current and former smoking on DNA methylation in an epigenome-wide approach using prospectively collected blood samples from healthy individuals who subsequently developed breast or colon cancer compared to matched controls. We hypothesised that smoking induces gene specific methylation,

1 Shenker et al.

2  
3 detectable in peripheral blood DNA and that these exposure induced changes may impact on  
4  
5 cancer risk.  
6  
7  
8  
9

## 10 **Results**

### 11 *Epigenome-wide association studies*

12  
13  
14  
15  
16  
17 In this study, we performed two epigenome-wide association studies (EWAS) on genomic  
18  
19 DNA from peripheral white blood cells (WBC) that were prospectively collected from two nested  
20  
21 case-control studies within a large cohort from the general population. All individuals were  
22  
23 healthy at the time of blood collection, but cases were selected from individuals who subsequently  
24  
25 developed either breast or colon cancer (average lag-time to diagnosis = 4.6 and 7 years,  
26  
27 respectively). These samples were being analysed to identify markers associated with breast  
28  
29 cancer and colon cancer risk and survival; however, these analyses are under-powered to detect  
30  
31 genome-wide significant individual markers and will need to be validated in larger sample sizes  
32  
33 currently underway (see Supplementary Figures 1-2). We have used this data in order to further  
34  
35 examine the association between methylation in peripheral blood genomic DNA from smokers  
36  
37 compared to former and non-smokers.(1) For the present analysis, we used multivariate linear  
38  
39 regression to investigate the association between DNA methylation levels and smoking status,  
40  
41 adjusting for age and batch. Using a cutoff of  $p < 1 \times 10^{-5}$ , we identified 17 and 19 loci in the breast  
42  
43 cancer and colon cancer EWAS, respectively, that were differentially methylated between  
44  
45 smokers, former smokers and those who had never smoked (Figure 1). Eight of these loci were  
46  
47 shared by both studies (Table 1). The top hits for both studies ( $p < 1 \times 10^{-5}$ ) are shown in  
48  
49 Supplemental Table 1. In all instances, the degree of methylation was lower in smokers than non-  
50  
51 smokers, and less difference was found between former smokers and non-smokers. Of note, the  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

1  
2  
3 *F2RL3* locus previously identified was in this list. There was no strong association ( $p < 1 \times 10^{-5}$ )  
4  
5 between methylation levels at any of these loci and disease status, despite smoking being a weak  
6  
7 risk factor for colon cancer (Supplementary Table 2).(2, 3) We observed no evidence for an  
8  
9 association between smoking and risk of colon cancer in this study ( $p = 0.857$ ), which was likely  
10  
11 to be a consequence of the small numbers of participants in the study. One of the smoking-  
12  
13 associated loci (cg01940273) at 2q37.1 showed an association with developing breast cancer, after  
14  
15 adjustment for smoking ( $p = 0.003$ ) and estrogen receptor status ( $p = 0.035$ ). This association  
16  
17 showed significant heterogeneity by smoking status as it associates with breast cancer case-  
18  
19 control status in a logistic regression model (Interaction  $P=0.039$ ). This region, therefore, warrants  
20  
21 further investigation in larger studies as a cancer risk marker and a mechanism for smoking-  
22  
23 induced carcinogenesis.  
24  
25  
26  
27  
28  
29  
30  
31

### ***Bisulphite pyrosequencing validation***

32  
33  
34 We used bisulphite pyrosequencing on an additional set of healthy subjects ( $n = 180$ ) to  
35  
36 validate the methylation association with smoking using an alternative method. We validated the  
37  
38 methylation of six CpG sites identified by the 450K array (2 CpG sites in *AHRR*, 2 CpG sites in  
39  
40 2q37, 1 CpG site in *F2RL3* and 1 CpG site in 6p21.33). The direction of methylation change and  
41  
42 effect sizes were of the same magnitude in the validation groups, and again, a significant  
43  
44 association with smoking was observed (Table 1). There was also remarkable evidence for an  
45  
46 association between methylation levels and smoking intensity for the *AHRR*, 2q37 and 6p21 loci  
47  
48 ( $p < 6.09 \times 10^{-5}$ ), but not *F2RL3*, with individuals smoking  $\geq 4$  cigarettes per day having  
49  
50 significantly lower methylation levels at these genomic loci (Supplementary Figure 4,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Supplementary Table 3). In former smokers, methylation levels at these genomic loci returned to

Shenker et al.

1  
2  
3 the levels of non-smokers with increasing time from cessation and those who had smoked more  
4  
5 intensively had methylation levels that were closer to that of current smokers (Supplementary  
6  
7 Figure 5).  
8  
9

10 Regional association plots showing the intragenic CpG island in *AHRR* and the intergenic CpG  
11 island at 2q37 are shown in Figure 2 with examples and pyrosequencing validation shown in  
12 Supplementary Figure 6. The CpG site in one of the *AHRR* regions of interest (*AHRR\_p1*,  
13 *cg23576855*) was also the site of a CG→CA SNP (*rs6869832*), with an A allele frequency of  
14 approximately 10% as confirmed by pyrosequencing (Figure 3). Minor allele (A) carriers (*n* = 31)  
15 were excluded from the pyrosequencing statistical analysis, as the cytosine could not be  
16 methylated in the CpA dinucleotide. Interestingly, three of the current smokers in the validation  
17 set were heterozygous carriers; their methylation levels (mean, 37.7%) were approximately half of  
18 the value found in smokers who were homozygous for the G allele (mean, 66.9%; Table 1). This  
19 indicated that the CpG site on the G allele was methylated to a similar degree as homozygous G  
20 alleles. We did not have genotyping data on the individuals in the EWAS sample sets, but predict  
21 that the individuals with ~40% and 5%  $\beta$ -values are likely to be heterozygous and homozygous  
22 for this SNP, respectively (Supplementary Figure 6).  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### ***Methylation and expression in human and mouse lung tissue***

43  
44  
45 Pyrosequencing assays were conducted on bisulphite-converted genomic DNA extracted from  
46  
47 27 human lung samples. We have investigated lung tissue in this case to assess the most relevant  
48  
49 tissue to the initial exposure. A marked association was present between smoking status and  
50  
51 methylation levels in human lung tissue. As in peripheral circulating mononuclear cell DNA,  
52  
53 methylation levels at *cg23576855* and *cg21161138* in the *AHRR* gene were significantly decreased in  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

1  
2  
3 current smokers ( $p = 0.00327$  and  $0.00143$ , respectively) (Figure 4A). The methylation values in  
4  
5 lung tissue were also identical to those shown in PBMCs, which suggests that blood sampling  
6  
7 could offer a useful surrogate for future biomarker studies of lung tissue methylation for this gene.  
8  
9

10 Expression analyses using qRT-PCR for *AHRR* in human lung samples from smokers vs.  
11 non-smokers ( $n = 5$  for each group) was inversely correlated with methylation levels ( $R^2=0.157$ )  
12 and showed increased expression by 5.7-fold ( $p = 0.0047$ ) in the current smokers compared to the  
13 non-smokers (Figure 4B). In a mouse model of smoke exposure (4), smoking significantly  
14 increased the levels of *Ahr* and *Cyp1a1* in a time-dependent manner compared to controls (Figure  
15 4C), while *Ahrr* expression was initially reduced 2.6-fold after the initial exposure to smoke (3 d;  
16  $p = 4.56 \times 10^{-6}$ ), but increased by 1.7-fold after 28 d ( $p = 0.003$ ). Methylation of the *Ahrr* locus was  
17 not performed as this intragenic CpG island region is not conserved in the mouse genome.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

## 32 Discussion

33  
34 The findings from these three groups of individuals give strong evidence for the role of  
35 smoking in inducing changes in DNA methylation levels. In this study, we have validated  
36 previously identified associations with methylation and smoking for the *F2RL3* and *AHRR* probes  
37 and have identified further *AHRR* probes that were significantly associated with smoking.(1, 5)  
38  
39 We have identified these in two cancer case-control studies using the Illumina 450K methylation  
40 beadchip and validated them by bisulphite pyrosequencing in an additional validation cohort. Our  
41 study has identified two novel loci, at 2q37.1 and 6p21, which are also strongly associated with  
42 smoking status. Importantly, we show for the first time that one of these loci, 2q37.1, is also  
43 associated with breast cancer risk. Lastly, we show that these associations between smoking and  
44 methylation are unlikely to be cell type specific differences due to different blood cell proportions.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

1  
2  
3 Previous evidence has suggested that intragenic methylation levels are correlated with  
4 expression levels, with highly expressed genes having high levels of intragenic methylation, and  
5 vice versa.(6-8) According to this rationale, we predicted that decreased levels of methylation in  
6 the *AHRR* gene in smokers would indicate lower levels of expression. In the smoke-exposed mice,  
7 this was indeed the case with short-term exposure (3 d), but the consequent increase in *Ahrr*  
8 expression after 28 d of smoke exposure suggest that other compensatory mechanisms of gene  
9 induction override the short-term decrease in expression marked by lower intragenic DNA  
10 methylation levels. This supports data that shows an increase in *Ahrr* expression following  
11 exposure to benzo(a)pyrene, a chemical found in cigarette smoke, in a mouse model.(9) In  
12 humans, the expression of *AHRR* in lung tissue mirrored the long term exposure in mice, however,  
13 the observed hypomethylation of this locus in lung tissue may be an indicator of past expression  
14 changes in this differentiated tissue type.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 A recent study of 165 individuals on the 450K methylation array identified a single CpG site  
32 within the *AHRR* gene associated with smoking status in EBV-transformed lymphoblastoid cell  
33 lines.(5) With a larger study size of 554 individuals, we have validated the association and  
34 identified additional intragenic CpG sites in the *AHRR* gene associated with smoking in white  
35 blood cell DNA and lung tissue. The aryl hydrocarbon receptor (AHR) is a crucial receptor in the  
36 pathway that metabolizes a range of biological compounds and synthetic environmental  
37 pollutants. Benzopyrene and dioxin-like compounds are highly toxic organic molecules that are  
38 released from various components of cigarettes during smoking and enter the circulation via the  
39 pulmonary vasculature. These compounds are metabolised by AhR,(10, 11) releasing further  
40 carcinogenic metabolites that have been implicated in lung cancer development.(12). However,  
41 the AHR pathway may also mediate carcinogenesis through other pathways such as oxidative  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

stress.(13) *AHRR* (aryl hydrocarbon receptor repressor; chromosome position 5p15.33) encodes for a class E basic helix-loop-helix protein,(14) which is mainly found in the cytoplasm. It inhibits the translocation of the AHR-ligand complex into the nucleus by disrupting the binding of AHR to the AHR-nuclear translocator (*AHRNT*).(15) The AHR-AHRNT heterodimer also inhibits the transcription of *AHRR* in a feedback loop. The knockdown of *AHRR* has been shown to produce increased tumour cell invasiveness in a range of tissue types, including breast, colon, lung, and ovarian. (16, 17) An increase of the repressor of the AHR pathway should lead to a decrease in the activity of the pathway, and therefore, a decrease in AHR pathway-mediated carcinogenesis. However, the data from our study shows an increase in *AHRR* expression and decreased intragenic methylation due to smoking, with no evidence of an association with breast or colon cancer risk. Therefore, more work is needed to understand the complex mechanisms of smoking induced carcinogenesis via the AHR pathway.

A novel finding of this study was that a genomic locus, comprising four consecutive probes at 2q37.1, was differentially methylated between smokers and former or non-smokers. The four probes are located within 824 bp of an intergenic CpG island (chr2: 233,284,112 – 233,284,935; <http://genome.ucsc.edu/>, hg19). This region maps to a DNase hypersensitivity site within a CpG island, indicating a possible regulatory region (Supplemental Figure 7),(18) and is a potential pseudogene of *ECELI* (endothelin-converting enzyme-like 1; chr2: 233,344,537 to 233,351,464 bp, 60,425 bp downstream of 2q37), as it possesses a high level of sequence homology (>95%). We observed an association with breast cancer risk at this locus with significant heterogeneity in the effect in smokers compared to non-smokers. While the estimate of breast cancer risk associated with smoking is still unclear (19), future work on larger case control studies will be needed to validate this cancer association. We hypothesize that molecular markers of smoking

Shenker et al.

1  
2  
3 exposure, such as methylation markers described here, will provide more accurate measurement  
4  
5 of the exposure than questionnaire based data and allow a more robust assessment of any  
6  
7 associated cancer risk. Whether this 2q37 locus is causally linked to breast cancer risk due to  
8  
9 smoking is not yet known, however, if verified we hypothesize that the mechanism may involve *in*  
10  
11 *cis* regulation of the developmentally regulated homologue, *ECELI*. There are several limitations  
12  
13 in establishing causality between an epigenetic trait, an exposure and cancer risk. These include  
14  
15 the reversible nature of epigenetic modifications and the need for an appropriate tissue type in  
16  
17 which to investigate gene expression – methylation associations (for example a large  
18  
19 epidemiology sized sample set of normal breast tissue prior to disease onset).  
20  
21  
22  
23

24  
25 A second novel intergenic locus with lower methylation levels in smokers was at 6p21.33 (chr  
26  
27 6: 307,020,080). This locus is in a gene desert which maps onto a DNase I hypersensitivity site  
28  
29 and transcription factor binding site, associated with an H3K27 acetylated chromatin site, which is  
30  
31 often associated with active regulatory elements. It is not associated with any gene or SNP.  
32  
33 Further studies will be required to assess the functional nature of these two novel intergenic  
34  
35 genomic loci.  
36  
37

38  
39 Toxic components of cigarette smoke enter the bloodstream via the alveolar capillary system,  
40  
41 after which they could directly affect the epigenetic profile of circulating WBC. For the loci that  
42  
43 correlated with smoking status, we showed a strong correlation with time since quitting and  
44  
45 duration of smoking, with methylation levels eventually returning to those of non-smoker levels.  
46  
47 This is an observation that has been seen for methylation at the *F2RL3* locus using the 27K  
48  
49 methylation chip,(20) and in the gene expression signature of smoking for some genes.(21)  
50  
51 Interestingly, the expression of some genes, including *AHRR*, do not return to previous levels,  
52  
53 which indicates a long-term gene expression consequence of prior smoking history that may be  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

1  
2  
3 locked in by DNA methylation changes.(21) However, we have to consider the possibility that  
4  
5 other confounding factors may influence this association. We and others have not adjusted for  
6  
7 alcohol and body mass index, which may be smoking-associated or methylation-associated  
8  
9 confounding factors. Furthermore, we have assessed methylation levels in the genomic DNA of  
10  
11 all circulating WBC. Smoking increases the circulating WBC count;(22) although the effect of  
12  
13 cigarette smoke on specific WBC types have not been assessed in large-scale populations, it may  
14  
15 be that subsets with different methylation levels are clonally expanded due to the exposure, which  
16  
17 might affect the overall methylation result. Using fractionation of blood cell types into T-cells, B-  
18  
19 cells, monocytes, granulocytes and buffy coat (all leukocytes) compared to whole blood cell DNA  
20  
21 from the same individuals we have shown no evidence that any of these blood cell types have  
22  
23 significantly different methylation levels that would confound the association with smoking  
24  
25 (Supplementary Table 6). Lastly, genetic haplotype differences between individuals tagging allele  
26  
27 specific methylation may confound associations with smoking status if such haplotypes are also  
28  
29 associated with smoking (23). We have performed a preliminary analysis of 25 individuals for  
30  
31 which we have both GWAS data and EWAS 450K methylation data (unpublished data). We  
32  
33 found evidence for potential allele specific methylation at the F2RL3 locus (general logistic  
34  
35 regression  $p=0.01$ ), but not for the other smoking associated loci (Supplementary Table 7). While  
36  
37 the AHRR CG>CA SNP (cg23576855, presented in Figure 3) does indeed influence the  
38  
39 methylation of this site and is in linkage disequilibrium with the haplotype tag SNP, it does not  
40  
41 influence allele specific methylation of the haplotype given that the two other nearby CpG sites  
42  
43 (79bp and 26,061 bp apart from the first site) show no evidence of allele specific methylation  
44  
45 ( $p=0.798$ ;  $p=0.916$ , respectively). Therefore, for the majority of loci it is unlikely that the  
46  
47 methylation association with smoking reported in this study is due to genetic polymorphism.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

1  
2  
3  
4  
5  
6 Taken together, these studies report a strong link between tobacco use and a direct biological  
7  
8 result on the epigenome, which is detectable in blood and lung tissue, and may impact on the  
9  
10 cancer risk associated with smoking. The level of methylation was directly associated with  
11  
12 smoking intensity and duration, however, the biological consequences of these epigenetic  
13  
14 alterations will require further investigation, particularly at these novel intergenic loci. The results  
15  
16 of our study and others regarding a key gene in the AHR pathway may have relevance beyond  
17  
18 tobacco smoke exposure given the key role played by this pathway in the metabolism of many  
19  
20 environmental carcinogens.  
21  
22  
23  
24  
25

## 26 27 **Materials and Methods**

### 28 29 *Subject recruitment*

30  
31 Study participants were drawn from the Italian component of the European Prospective  
32  
33 Investigation into Cancer and Nutrition cohort, a large general population cohort consisting of  
34  
35 ~520,000 individuals with standardised lifestyle and personal history questionnaires,  
36  
37 anthropometric data and blood samples collected for DNA extraction.(24, 25) In this study, we  
38  
39 used the Torino sub-cohort (EPIC-Turin) which consists of ~10,000 subjects. For the microarray  
40  
41 component of this study we included 92 incident female breast cancer cases and 92 matched  
42  
43 controls and 95 incident colon cancer cases and 95 matched controls including 68 male and 27  
44  
45 female pairs. Controls were individually matched on age ( $\pm 5$  years), sex, seasonality of blood  
46  
47 collection and duration of follow-up. Blood samples from cancer cases were taken 55 months  
48  
49 before diagnosis on average (range, 24-108 months) for breast cancer cases and 84 months before  
50  
51 diagnosis (range, 0.2-173 months) for colon cancer cases (Supplementary Table 5). Blood cell  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Shenker et al.

2  
3 type fractionation was performed on six healthy volunteers using magnetic bead separation  
4  
5 (EasySep, StemCell Technologies, France).  
6  
7

### 8 9 10 ***Microarray protocol***

11  
12 For the microarray, DNA samples were extracted using the QIASymphony DNA Midi Kit  
13 (Qiagen, Crawley, UK). Bisulphite conversion of 500 ng of each sample was performed using the  
14 EZ-96 DNA Methylation-Gold™ Kit (Zymo Research, Orange, CA). Bisulphite-converted DNA  
15 was used for hybridisation on the Infinium HumanMethylation 450 BeadChip, following the  
16 Illumina Infinium HD Methylation protocol. The methylation score for each CpG was represented  
17 as a  $\beta$ -value according to the fluorescent intensity ratio representing any value between 0  
18 (unmethylated) and 1 (completely methylated). Raw microarray data and processed normalised  
19 data will be available from Gene Expression Omnibus (GEO) (accession TBA).  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 ***Validation of array-based methylation results by pyrosequencing***

35  
36 For the validation component of this study, 180 healthy control individuals were randomly  
37 sampled from females enrolled in the EPIC-Turin cohort. This group comprised 33 current  
38 smokers, 45 former smokers and 102 individuals who had never smoked. Genomic DNA (250 ng)  
39 from each subject was bisulphite converted as above. For pyrosequencing, specific primers were  
40 designed for six CpG loci using PyroMark software (Qiagen, Hilden Germany), and PCR  
41 conditions were as described previously.(26) (Supplemental Table 6). Methylation values were  
42 calculated as an average of all high quality CpG sites, which were determined as “passed” by the  
43 quality control thresholds within the Pyro Q-CpG software (Qiagen). Pyrosequencing assays for  
44 three loci (cg05951221, cg01940273 and cg05575921) could not be designed.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

### ***Human and murine expression analyses***

Human lung samples (n=27, 14 smokers, 13 non-smokers) were obtained from either lung transplants performed at The Royal Brompton or Harefield Hospital or purchased from IIAM (International Institute for the Advancement of Medicine, Edison, NJ). In all cases, the tissue was consented for use in scientific research and ethics approval obtained from the Royal Brompton & Harefield Trust. DNA was extraction and pyrosequencing was performed as described above. RNA was extracted from lung tissue (n=5 smokers, n=5 non-smokers), and quantitative RT-PCR (qRT-PCR) was performed on a Bio-Rad PCR machine with SyBR green (Sigma), for *AHRR* normalised against *GAPDH*, using standard protocols. Lung tissue was collected from ten mice exposed to air (n=5) or cigarette smoke (n=5), as described previously.(7) RNA was extracted and qRT-PCR was performed for *Ahrr*, *Ahr*, *Cyp1a1* and *F2rl3* as described above, using a ribosomal gene, *Rpl7*, as the internal reference standard.

### ***Statistical analysis***

For the statistical analysis, raw data was exported from GenomeStudio (Illumina) as background subtracted  $\beta$ -values with corresponding detection p-values. Following quality control the resulting data sets included 86 breast cancer cases with 87 matched controls (86 matched pairs) and 95 colon cancer cases and 95 matched controls. Overall, 484,804 probes were analysed in the breast cancer data set and 485,152 in the colon cancer data set. There were no significant genome-wide methylation differences between smokers, former and never smokers in raw  $\beta$ -values (Supplementary Figure 6); therefore, the data was normalised using quantile normalisation. Multivariate linear regression was used to identify associations between methylation  $\beta$ -values as

Shenker et al.

1  
2  
3 the outcome and coded smoking status as the exposure (0, 1 and 2 for ‘Never’, ‘Former’ and  
4  
5 ‘Current’ smokers, respectively), adjusting for age and batch. A secondary analysis was  
6  
7 performed that also adjusted for case-control status, which did not significantly alter the results  
8  
9 (Supplementary Table 2). P-values less than  $1 \times 10^{-7}$  were considered to be significant at the level  
10  
11 of epigenome-wide significance. We found no evidence for a bias towards probes containing  
12  
13 SNPs or type I or type II probes in probes associated with smoking. For association with smoking  
14  
15 intensity, coded intensity categories were used as the exposure, Time to quitting and duration of  
16  
17 smoking in former smokers were analysed as continuous variables. Attributable risk for the 2q37  
18  
19 locus was calculated as the difference in rate of hypomethylation between an exposed population  
20  
21 (cancer cases) and an unexposed population (healthy controls), stratified by smoking status. All  
22  
23 analyses were performed in R, v2.13.1. Gene expression levels were compared between the  
24  
25 control and smoke-exposed human or mouse lung tissue using Student’s t-tests with  $P < 0.05$   
26  
27 considered significant.  
28  
29  
30  
31  
32  
33  
34  
35

### **Acknowledgements**

36  
37 JMF is funded by a Breast Cancer Campaign Fellowship. JMF and RB acknowledge funding from  
38  
39 Cancer Research UK (A13086) and the Imperial Biomedical Research Centre. PV is funded by  
40  
41 the HuGeF Foundation, Torino, Italy. NS is funded by a Medical Research Council UK graduate  
42  
43 scholarship. The human tissue experiments in this study were undertaken with the support of the  
44  
45 NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS  
46  
47 Foundation Trust and Imperial College London.  
48  
49  
50  
51

### **Statement of competing financial interests**

Shenker et al.

None declared.

**Supplemental Data**

Supplemental data include supplementary methods, seven figures and seven tables (see attached files).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

## References

1. Breitling, L.P., Yang, R., Korn, B., Burwinkel, B. and Brenner, H. (2011) Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. *Am. J. Hum. Genet.*, **88**, 450-457.
2. Sasco, A.J., Secretan, M.B. and Straif, K. (2004) Tobacco smoking and cancer: a brief review of recent epidemiological evidence. *Lung Cancer* , **45** Suppl 2, S3-S9.
3. Hannan, L.M., Jacobs, E.J. and Thun, M.J. (2009) The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. *Cancer Epidemiol. Biomarkers Prev.*, **18**, 3362-3367.
4. Eltom, S., Stevenson, C.S., Rastrick, J., Dale, N., Raemdonck, K., Wong, S., Catley, M.C., Belvisi, M.G. and Birrell, M.A. (2011) P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. *PloS One*, **6**, e24097.
5. Monick, M.M., Beach, S.R., Plume, J., Sears, R., Gerrard, M., Brody, G.H. and Philibert, R.A. (2012) Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers. *Am. J. Med. Genet. B Neuropsychiatr. Genet.*, **159B**, 141-151.

Shenker et al.

- 1  
2  
3 6. Zilberman, D., Gehring, M., Tran, R.K., Ballinger, T. and Henikoff, S. (2007) Genome-wide  
4  
5 analysis of *Arabidopsis thaliana* DNA methylation uncovers an interdependence between  
6  
7 methylation and transcription. *Nat. Genet.*, **39**, 61-69.  
8  
9
- 10  
11  
12 7. Aran, D., Toperoff, G., Rosenberg, M. and Hellman, A. (2011) Replication timing-related and  
13  
14 gene body-specific methylation of active human genes. *Hum. Mol. Genet.*, **20**, 670-680.  
15  
16  
17
- 18  
19  
20 8. Shenker, N. and Flanagan, J.M. (2012) Intragenic DNA methylation: implications of this  
21  
22 epigenetic mechanism for cancer research. *Br. J. Cancer*, **106**, 248-253.  
23  
24  
25
- 26  
27 9. Bernshausen, T., Jux, B., Esser, C., Abel, J. and Fritsche, E. (2006) Tissue distribution and  
28  
29 function of the Aryl hydrocarbon receptor repressor (AhRR) in C57BL/6 and Aryl hydrocarbon  
30  
31 receptor deficient mice. *Arch. Toxicol.*, **80**, 206-211.  
32  
33  
34
- 35  
36 10. Moennikes, O., Loeppen, S., Buchmann, A., Andersson, P., Itrich, C., Poellinger, L. and  
37  
38 Schwarz, M. (2004) A constitutively active dioxin/aryl hydrocarbon receptor promotes  
39  
40 hepatocarcinogenesis in mice. *Cancer Res.*, **64**, 4707-4710.  
41  
42  
43
- 44  
45 11. Shimizu, Y., Nakatsuru, Y., Ichinose, M., Takahashi, Y., Kume, H., Mimura, J., Fujii-  
46  
47 Kuriyama, Y. and Ishikawa, T. (2000) Benzo[a]pyrene carcinogenicity is lost in mice lacking  
48  
49 the aryl hydrocarbon receptor. *Proc. Natl. Acad. Sci. USA.*, **97**, 779-782.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

12. Chiba, T., Uchi, H., Yasukawa, F. and Furue, M. (2012) Role of the arylhydrocarbon receptor in lung disease. *Int. Arch. Allergy. Immunol.*, **155 Suppl 1**, 129-134.
13. Cheng, Y.H., Huang, S.C., Lin, C.J., Cheng, L.C. and Li, L.A. (2012) Aryl hydrocarbon receptor protects lung adenocarcinoma cells against cigarette sidestream smoke particulates-induced oxidative stress. *Toxicol. Appl. Pharmacol.*, **259**, 293-301.
14. Baba, T., Mimura, J., Gradin, K., Kuroiwa, A., Watanabe, T., Matsuda, Y., Inazawa, J., Sogawa, K. and Fujii-Kuriyama, Y. (2001) Structure and expression of the Ah receptor repressor gene. *J. Biol. Chem.*, **276**, 33101-33110.
15. Evans, B.R., Karchner, S.I., Allan, L.L., Pollenz, R.S., Tanguay, R.L., Jenny, M.J., Sherr, D.H. and Hahn, M.E. (2008) Repression of aryl hydrocarbon receptor (AHR) signaling by AHR repressor: role of DNA binding and competition for AHR nuclear translocator. *Mol. Pharmacol.*, **73**, 387-398.
16. Zudaire, E., Cuesta, N., Murty, V., Woodson, K., Adams, L., Gonzalez, N., Martinez, A., Narayan, G., Kirsch, I., Franklin, W. *et al.* (2008) The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. *J. Clin. Invest.*, **118**, 640-650.
17. Kanno, Y., Takane, Y., Izawa, T., Nakahama, T. and Inouye, Y. (2006) The inhibitory effect of aryl hydrocarbon receptor repressor (AhRR) on the growth of human breast cancer MCF-7 cells. *Biol. Pharm. Bull.*, **29**, 1254-1257.

Shenker et al.

- 1  
2  
3  
4  
5  
6 18. Crawford, G.E., Holt, I.E., Whittle, J., Webb, B.D., Tai, D., Davis, S., Margulies, E.H.,  
7  
8 Chen, Y., Bernat, J.A., Ginsburg, D. *et al.* (2006) Genome-wide mapping of DNase  
9  
10 hypersensitive sites using massively parallel signature sequencing (MPSS). *Genome Res.*, **16**,  
11  
12 123-131.  
13  
14  
15  
16  
17  
18 19. Cox, D.G., Dostal, L., Hunter, D.J., Le Marchand, L., Hoover, R., Ziegler, R.G. and Thun,  
19  
20 M.J. (2011) N-acetyltransferase 2 polymorphisms, tobacco smoking, and breast cancer risk in  
21  
22 the breast and prostate cancer cohort consortium. *Am. J. Epidemiol.*, **174**, 1316-1322.  
23  
24  
25  
26  
27 20. Wan, E.S., Qiu, W., Baccarelli, A., Carey, V.J., Bacherman, H., Rennard, S.I., Agusti, A.,  
28  
29 Anderson, W., Lomas, D.A. and Demeo, D.L. (2012) Cigarette smoking behaviors and time  
30  
31 since quitting are associated with differential DNA methylation across the human genome.  
32  
33 *Hum. Mol. Genet.*, **21**, 3073-3082.  
34  
35  
36  
37  
38  
39 21. Bosse, Y., Postma, D.S., Sin, D.D., Lamontagne, M., Couture, C., Gaudreault, N., Joubert,  
40  
41 P., Wong, V., Elliott, M., van den Berge, M. *et al.* (2012) Molecular signature of smoking in  
42  
43 human lung tissues. *Cancer Res.*, **72**, 3753-3763.  
44  
45  
46  
47  
48 22. Wannamethee, S.G., Lowe, G.D., Shaper, A.G., Rumley, A., Lennon, L. and Whincup,  
49  
50 P.H. (2005) Associations between cigarette smoking, pipe/cigar smoking, and smoking  
51  
52 cessation, and haemostatic and inflammatory markers for cardiovascular disease. *Eur. Heart*  
53  
54 *J.*, **26**, 1765-1773.  
55  
56  
57  
58  
59  
60

Shenker et al.

- 1  
2  
3  
4  
5  
6 23. Munafo, M.R., Timofeeva, M.N., Morris, R.W., Prieto-Merino, D., Sattar, N., Brennan, P.,  
7  
8 Johnstone, E.C., Relton, C., Johnson, P.C., Walther, D. *et al.* (2012) Association between  
9  
10 genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. *J.*  
11  
12 *Natl. Cancer Inst.*, **104**, 740-748.  
13  
14  
15  
16  
17 24. Riboli, E. and Kaaks, R. (1997) The EPIC Project: rationale and study design. European  
18  
19 Prospective Investigation into Cancer and Nutrition. *Int. J. Epidemiol.*, **26 Suppl 1**, S6-S14.  
20  
21  
22  
23  
24 25. Riboli, E. (2001) The European Prospective Investigation into Cancer and Nutrition  
25  
26 (EPIC): plans and progress. *J. Nutr.*, **131**, 170S-175S.  
27  
28  
29  
30  
31 26. Flanagan, J.M., Cocciardi, S., Waddell, N., Johnstone, C.N., Marsh, A., Henderson, S.,  
32  
33 Simpson, P., da Silva, L., Khanna, K., Lakhani, S. *et al.* (2010) DNA methylome of familial  
34  
35 breast cancer identifies distinct profiles defined by mutation status. *Am. J. Hum. Genet.*, **86**,  
36  
37 420-433.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Shenker et al.

## Figure Legends

**Figure 1: Manhattan plot and quantile-quantile plot for EWAS results for smoking status in two case-control studies.**

A) Breast cancer case-control study. B) Colon cancer case-control study. In the Manhattan plot, the vertical axis indicates ( $-\log_{10}$  transformed) observed p-values, and the horizontal thresholds indicate the significance levels of  $p = 1 \times 10^{-5}$  and  $p = 1 \times 10^{-7}$ . In the quantile-quantile (QQ) plot, the horizontal axis shows ( $-\log_{10}$  transformed) expected p-values, and the vertical axis indicates ( $-\log_{10}$  transformed) observed p-values. The lambda inflation factor ( $\text{median}[\text{obs}]/\text{median}[\text{exp}]$ ) is shown.

**Figure 2: Regional association plots showing two regions associated with smoking status AHRR (A) and 2q37.1 intergenic CpG island (B).** Regional association plots are shown with the gene map (from UCSC genome browser, hg19) with a graph of  $-\log_{10}$  p-values on the y-axis and nucleotide position on the x-axis for the breast cancer EWAS (blue diamonds), colon cancer EWAS (red circles) and pyrosequencing validation (black asterisks).

**Figure 3: Pyrosequencing validation of AHRR locus cg23576855 reveals a CG>CA single nucleotide polymorphism (rs6869832).** Boxplots represent pyrosequencing-based methylation levels of individuals with the homozygous G allele in the validation control population. Heterozygotes and homozygotes for the minor A allele are marked as a cross and show the same relationship to smoking status.

Shenker et al.

**Figure 4: Smoking induces methylation and expression changes in human and mouse lung tissue.** A) Pyrosequencing data from two regions of interest, presented as boxplots, in human lung tissue samples from smokers (n=14) vs. never smokers (n=13). For cg23576855 individuals heterozygous for the CG>CA polymorphism are marked as crosses. B) AHRR mRNA expression data from human lung tissue from smokers (n=5) versus non-smokers (n=5), showing a 5.7-fold increase in expression in smokers compared to non-smokers (upper panel) and correlation between methylation and expression in the same 5 non-smokers (grey circles) and 5 smokers (black triangles) (lower panel). C) Mouse lung expression changes in AHRR and F2RL3, in addition to two other genes from the aryl hydrocarbon receptor pathway, AHR and CYP1A1. As predicted, AHR and CYP1A1 increase in response to cigarette smoke, and the expression of AHRR initially decreases after 3 days, before increasing after 28 days. There was no significant change in the expression of F2RL3 after exposure to cigarette smoke.

Shenker et al.

**Table 1: Leading differentially methylated genomic loci between smokers and former or non-smokers in a breast and colonic case-control cohort.** This list contains the top eight overlapping CG sites between the breast cancer and colon cancer EWAS studies, in addition to an additional site within the 2q37.1 locus that was also validated by pyrosequencing. Rows in bold indicate the data that was independently validated by bisulphite pyrosequencing of that locus in a separate EPIC cohort of healthy individuals (n = 180) with known smoking status.

Chr, chromosome; FDR, false discovery rate; nd, not done; n/a, not applicable.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Target ID	Chr	MAPINFO (bp)	Symbol	B-values in breast cancer case-control cohort					B-values in colon cancer case-control cohort					Pyrosequencing methylation in the validation cohort				
				Never	Former	Current	P-value *	Effect size (%) **	Never	Former	Current	P-value *	Effect size (%) **	Never	Former	Current	P-value (FDR)	Effect size (%) **
<b>cg06644428</b>	<b>2</b>	<b>233284112</b>	<b>2q37.1</b>	<b>0.07</b>	<b>0.05</b>	<b>0.05</b>	<b>6.17E-07</b>	<b>2</b>	<b>0.11</b>	<b>0.09</b>	<b>0.09</b>	<b>3.38E-04</b>	<b>3</b>	<b>12.11</b>	<b>11.02</b>	<b>8.11</b>	<b>1.48E-05</b>	<b>4</b>
cg05951221	2	233284402	2q37.1	0.39	0.33	0.28	1.80E-13	11	0.41	0.37	0.34	1.83E-07	7					
<b>cg21566642</b>	<b>2</b>	<b>233284661</b>	<b>2q37.1</b>	<b>0.44</b>	<b>0.37</b>	<b>0.32</b>	<b>3.73E-13</b>	<b>12</b>	<b>0.51</b>	<b>0.47</b>	<b>0.39</b>	<b>4.41E-08</b>	<b>12</b>	<b>58.86</b>	<b>53.04</b>	<b>40.11</b>	<b>2.22E-08</b>	<b>18.75</b>
cg01940273	2	233284934	2q37.1	0.58	0.56	0.49	1.47E-10	9	0.62	0.59	0.54	5.96E-09	8					
<b>cg23576855</b>	<b>5</b>	<b>373299</b>	<b>AHRR</b>	<b>0.66</b>	<b>0.64</b>	<b>0.5</b>	<b>3.46E-06</b>	<b>16</b>	<b>0.73</b>	<b>0.68</b>	<b>0.53</b>	<b>9.66E-06</b>	<b>20</b>	<b>82.68</b>	<b>80.17</b>	<b>66.91</b>	<b>1.51E-12</b>	<b>15.77</b>
cg05575921	5	373378	AHRR	0.84	0.79	0.68	2.31E-15	17	0.84	0.81	0.7	1.73E-09	14					
<b>cg21161138</b>	<b>5</b>	<b>399360</b>	<b>AHRR</b>	<b>0.66</b>	<b>0.65</b>	<b>0.6</b>	<b>5.44E-08</b>	<b>5</b>	<b>0.72</b>	<b>0.71</b>	<b>0.68</b>	<b>8.29E-06</b>	<b>4</b>	<b>75.47</b>	<b>74.67</b>	<b>68.3</b>	<b>3.22E-05</b>	<b>7.17</b>
<b>cg03636183</b>	<b>19</b>	<b>17000585</b>	<b>F2RL3</b>	<b>0.64</b>	<b>0.61</b>	<b>0.56</b>	<b>8.38E-11</b>	<b>8</b>	<b>0.68</b>	<b>0.65</b>	<b>0.61</b>	<b>3.84E-07</b>	<b>7</b>	<b>62.19</b>	<b>60.92</b>	<b>54.32</b>	<b>0.00172</b>	<b>7.87</b>
<b>cg06126421</b>	<b>6</b>	<b>30720080</b>	<b>6p21.33</b>	<b>0.65</b>	<b>0.61</b>	<b>0.57</b>	<b>4.96E-11</b>	<b>8</b>	<b>0.71</b>	<b>0.7</b>	<b>0.64</b>	<b>2.46E-06</b>	<b>7</b>	<b>67.4</b>	<b>66.8</b>	<b>59.5</b>	<b>0.00095</b>	<b>7.88</b>

\* Logistic regression adjusting for age and batch effect; \*\* effect size represents percentage methylation difference between current smokers and individuals who have never smoked. Pyrosequencing assays could not be designed for three of the nine CpG sites.



Shenker et al.

**Abbreviations**

AHR, aryl hydrocarbon receptor

AHRR, aryl hydrocarbon receptor repressor

CpG, cytosine-guanine dinucleotide


EWAS, epigenome-wide association study

F2RL3, coagulation factor II (thrombin) receptor-like 3


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

**A**

Methylation Associated with Smoking




QQ plot - Smoking




**B**



Methylation Associated with Smoking



QQ plot - Smoking



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

